Friedemann Honecker1,2, Ulrich Wedding3, Gerd Kallischnigg4, Axel Schroeder5, Jörg Klier6, Thomas Frangenheim7, Lothar Weißbach8. 1. Tumor and Breast Center ZeTuP St Gallen, Rorschacher Str 150, 9006, St Gallen, Switzerland. 2. Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg, Martinistr. 52, 20246, Hamburg, Germany. 3. Department of Palliative Care, University Hospital, Am Klinikum 1, 07747, Jena, Germany. 4. ARGUS- Statistics and Information Systems in Environment and Public Health GmbH, Karl-Heinrich-Ulrich Str. 20a, 10785, Berlin, Germany. 5. Medical Specialist for Urology, Haart 87-89, 24534, Neumünster, Germany. 6. Medical Specialist for Urology, Andrology, Palliative Medicine and Medical Tumour Therapy, UroOncology, Bernhardstr. 110, 50968, Cologne, Germany. 7. Medical Specialist for Urology, Kaiserstr. 17, 76646, Bruchsal, Germany. 8. Gesundheitsforschung für Männer gGmbH, Claire-Waldoff-Str. 3, 10117, Berlin, Germany. weissbach@gesundheitsforschung-fuer-maenner.de.
Abstract
PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons for and factors associated with discontinuation of scheduled treatment were analysed by univariate and multivariate analysis. RESULTS: After inclusion of 177 of 300 planned patients, the study was closed due to slow recruitment. 160 patients were eligible for final analysis. Median age was 77.5 years. 46% received chemotherapy, and 54% hormonal treatment. Discontinuation of scheduled treatment occurred in 91 patients (57.6%). The main reasons were progressive disease/death in 63%, adverse events/toxicity in 22%, and withdrawal of consent in 8%. In bivariate analyses, factors associated with discontinuation of treatment were age ≥ 80 years, ECOG PS ≥ 2, compromised/poor health status (physicians'/patients' assessment), and compromised functional or nutritional status. In multivariate analysis, the only remaining factor independently associated with discontinuation of scheduled treatment was impairment of activities of daily living (ADL < 100 points) (OR = 4.2 for discontinuation; p < 0.05). CONCLUSION: Despite limitations due to early termination of the study, our results demonstrate that discontinuation of scheduled treatment was common, and that compromised ADL seems to be a significant risk factor for treatment failure in elderly patients with CRPC.
PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS:Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons for and factors associated with discontinuation of scheduled treatment were analysed by univariate and multivariate analysis. RESULTS: After inclusion of 177 of 300 planned patients, the study was closed due to slow recruitment. 160 patients were eligible for final analysis. Median age was 77.5 years. 46% received chemotherapy, and 54% hormonal treatment. Discontinuation of scheduled treatment occurred in 91 patients (57.6%). The main reasons were progressive disease/death in 63%, adverse events/toxicity in 22%, and withdrawal of consent in 8%. In bivariate analyses, factors associated with discontinuation of treatment were age ≥ 80 years, ECOG PS ≥ 2, compromised/poor health status (physicians'/patients' assessment), and compromised functional or nutritional status. In multivariate analysis, the only remaining factor independently associated with discontinuation of scheduled treatment was impairment of activities of daily living (ADL < 100 points) (OR = 4.2 for discontinuation; p < 0.05). CONCLUSION: Despite limitations due to early termination of the study, our results demonstrate that discontinuation of scheduled treatment was common, and that compromised ADL seems to be a significant risk factor for treatment failure in elderly patients with CRPC.
Authors: Hans Wildiers; Murielle Mauer; Athanasios Pallis; Arti Hurria; Supriya G Mohile; Andrea Luciani; Giuseppe Curigliano; Martine Extermann; Stuart M Lichtman; Karla Ballman; Harvey Jay Cohen; Hyman Muss; Ulrich Wedding Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: L Decoster; K Van Puyvelde; S Mohile; U Wedding; U Basso; G Colloca; S Rostoft; J Overcash; H Wildiers; C Steer; G Kimmick; R Kanesvaran; A Luciani; C Terret; A Hurria; C Kenis; R Audisio; M Extermann Journal: Ann Oncol Date: 2014-06-16 Impact factor: 32.976
Authors: A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers Journal: Eur J Cancer Date: 2010-03-12 Impact factor: 9.162
Authors: C A Bellera; M Rainfray; S Mathoulin-Pélissier; C Mertens; F Delva; M Fonck; P L Soubeyran Journal: Ann Oncol Date: 2012-01-16 Impact factor: 32.976
Authors: Jean-Pierre Droz; Matti Aapro; Lodovico Balducci; Helen Boyle; Thomas Van den Broeck; Paul Cathcart; Louise Dickinson; Eleni Efstathiou; Mark Emberton; John M Fitzpatrick; Axel Heidenreich; Simon Hughes; Steven Joniau; Michael Kattan; Nicolas Mottet; Stéphane Oudard; Heather Payne; Fred Saad; Toru Sugihara Journal: Lancet Oncol Date: 2014-08 Impact factor: 41.316